|
1）Young SG, Davies BS, Fong LG, et al. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol. 2007; 18: 389-96
|
|
|
|
2）Yamamoto H, Onishi M, Miyamoto N, et al. Novel combined GPIHBP1 mutations in a patient with hypertriglyceridemia associated with CAD. J Atheroscler Thromb. 2013; 20: 777-84
|
|
|
|
|
3）Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-6
|
|
|
|
|
|
4）Zelcer N, Hong C, Boyadjian R, et al. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009; 325: 100-4
|
|
|
|
|
|
5）Beaumont JL. Auto-immune hyperlipidemia. An atherogenic metabolic disease of immune origin. Rev Eur Etud Clin Biol. 1970; 15: 1037-41
|
|
|
|
|
|
6）Kihara S, Matsuzawa Y, Kubo M, et al. Autoimmune hyperchylomicronemia. N Engl J Med. 1989; 320: 1255-9
|
|
|
|
|
|
7）Cortese C, Lewis B, Miller NE, et al. Myelomatosis with type III hyperlipoproteinemia: clinical and metabolic studies. New Engl J Med. 1982; 307: 79-83
|
|
|
|
|
|
8）Reckless JP, Stocks J, Holdsworth G, et al. Studies of a variant very-low-density lipoprotein with an acquired deficiency of apolipoprotein C-II. Clin Sci(Lond). 1982; 62: 93-100
|
|
|
|
|
|
9）Kilgore LL, Patterson BW, Parenti DM, et al. Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma. Characterization of this immunoglobulin. J Clin Invest. 1985; 76: 225-32
|
|
|
|
|
|
10）Corsini A, Roma P, Sommariva D, et al. Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia. J Clin Invest. 1986; 78: 940-6
|
|
|
|
|
|
11）Pauciullo P, De Simone B, Rubba P, et al. A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment. J Endocrinol Invest. 1986; 9: 517-20
|
|
|
|
|
|
12）Okamoto Y, Tominaga K, Uemura S, et al. Hypertriglyceridemia caused by the autoantibody to lipases for plasma lipoproteins: a case report. J Atheroscler Thromb. 1995; 2: 66-9
|
|
|
|
|
|
13）Nozaki S, Ito Y, Nakagawa T, et al. Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. Intern Med. 1997; 36: 920-5
|
|
|
|
|
|
14）Pruneta V, Moulin P, Labrousse F, et al. Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy. J Clin Endocrinol Metab. 1997; 82: 791-6
|
|
|
|
|
|
15）Yoshimura T, Ito M, Sakoda Y, et al. Rare case of autoimmune hyperchylomicronemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1998; 76: 49-51
|
|
|
|
|
|
16）Rumbo C, Betzhold J, Merati S, et al. Autoimmune hyperlipidemia in a child with autoimmune hepatitis. J Clin Gastroenterol. 2002; 35: 196-9
|
|
|
|
|
|
17）Pruneta-Deloche V, Marcais C, Perrot L, et al. Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia. J Clin Endocrinol Metab. 2005; 90: 3995-8
|
|
|
|
|
|
18）Michel M, Fois E, Niault M, et al. Severe autoimmune type V hyperlipidemia preceding a systemic lupus erythematosus in a 15 year-old girl. Lupus. 2007; 16: 378-9
|
|
|
|
|
|
19）Ashraf AP, Beukelman T, Pruneta-Deloche V, et al. Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogrenʼs syndrome. J Clin Endocrinol Metab. 2011; 96: 3302-7
|
|
|
|
|
|
20）Vik A, Isaksen V, Brox J, et al. [Middle-aged female presenting with headache, blurred vision and skin rash]. Tidsskr Nor Laegeforen. 2012; 132: 1246-8
|
|
|
|
|
|
21）de Carvalho JF, Borba EF, Viana VS, et al. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum. 2004; 50: 3610-5
|
|
|
|
|
|
22）Kodera M, Hayakawa I, Komura K, et al. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. J Rheumatol. 2005; 32: 629-36
|
|
|
|
|
|
23）Reichlin M, Fesmire J, Quintero-Del-Rio AI, et al. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 2957-63
|
|
|
|
|
|
24）de Carvalho JF, Viana VS, Neto EF, et al. Antilipoprotein lipase antibodies in patients with hypertriglyceridemia without associated autoimmune disease. Isr Med Assoc J. 2011; 13: 350-3
|
|
|
|
|
|
25）Moret M, Pruneta-Deloche V, Sassolas A, et al. Prevalence and function of anti-lipoprotein lipase auto-antibodies in type V hyperchylomicronemia. Atherosclerosis. 2010; 208: 324-7
|
|
|
|
|
|
26）Yamamoto H, Tanaka M, Yoshiga S, et al. Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody. J Clin Endocrinol Metab. 2014; 99: 1525-30
|
|
|
|
|
|
27）Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014; 370: 1809-19
|
|
|
|
|
|
28）Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012; 366: 1108-18
|
|
|
|
|
|
29）Hayden MR, Liu MS, Ma Y. Gene environment interaction and plasma triglyceride levels: the crucial role of lipoprotein lipase. Clin Genet. 1994; 46: 15-8
|
|
|
|
|
|
30）Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007; 176: 1113-20
|
|
|
|
|
|
31）Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab. 2007; 92: 1581-9
|
|
|
|
|